Transfusion and Thromboembolic Prophylaxis

  • B. Borghi
  • M. Montebugnoli
  • N. De Simone
  • G. Gargioni
  • M. A. Feoli


The number of units and frequency of transfusion is decided by the anesthetist together with the physician performing the transfusion during the first examination, which should take place at least 40 days prior to the operation, according to the clinical condition of the patient (age, weight, basal hemoglobin, any concomitant diseases) and the type of operation and expected perioperative blood loss (1). A subtraction of 350 ± 10% ml of blood from a patient weighing about 70 kg means a reduction of around 1 g of hemoglobin (Hb) and 3 units of hematocrit (Ht). Before major orthopedic surgery enough units should be predeposited so as to avoid the use of homologous blood in more than 90% of patients. Two units of autologous blood are generally needed for total knee and hip arthroplasty and spine fusion, and 3-4 units for partial or total knee or hip revision.


Partial Activate Thromboplastin Time Autologous Blood Major Orthopedic Surgery Homologous Blood Thromboembolic Prophylaxis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Borghi B, Bassi A, de Simone N, Laguardia AM, Formaro G (1993) Autotransfusion: 15 years experience at Rizzoh Orthopaedic Institute. Int J Artif Organs 16(S-5):241–246PubMedGoogle Scholar
  2. 2.
    Borghi B, Bassi A, Grazia M, Gargioni G, Pignotti E (1995) Anaesthesia and autologous transfusion. Int J Artif Orpns 18(3):159–166Google Scholar
  3. 3.
    National Resuree Education Program Coordinating Committee National Institute of Health (1989) Summary Report, BethesdaGoogle Scholar
  4. 4.
    Oriani G, Gaietta T, Meazza D, Ronzio A, Sacchi C (1990) Ematocrito di sicurezza in chirurgia ortopedico-traumatologica. Atti XX Corso Naz. di Aggiornamento in Rianimazione e Terapia intensiva. Ed Piccin, Padova, pp 19–27Google Scholar
  5. 5.
    Borghi B, Oriani G, Bassi A et al (1995) Blood saving program: a multicenter Italian experience. Int J Artif Organs 18(3):150–158PubMedGoogle Scholar
  6. 6.
    Bombardini T, Borghi B, Caroli GC et al (1994) Short term cardiac adaptation to normovolemic hemodilution in normal and hypertensive patients. An echocardiography study. Eur Heart J 15:637–640PubMedGoogle Scholar
  7. 7.
    Vara-Thorbeck R, Rossel Pradas J, Mekinassi KL et al (1990) Prevention of thrombotic disease and post-transfusional complication using normovolemic hemodilution in arthroplasty surgery of the hip. Rev Chir Orthop 76(4):267–271PubMedGoogle Scholar
  8. 8.
    Bombardini T, Borghi B, Montebugnoli M, Picano E, Caroli GC (1995) Normovolemic hemodilution reduces fatal pulmonary embolism: following major orthopaedic surgery. J Vase Surg (in press)Google Scholar
  9. 9.
    Baron JF et al (1989) Hemodilution, autotransfusion, hemostase. Arnette, Paris, pp 396Google Scholar
  10. 10.
    Messmer K (1988) Haemodilution. Possibihties and safety aspects. Acta Anaesthesiol Scand Suppl 89:49–53PubMedCrossRefGoogle Scholar
  11. 11.
    Duruble M (1988) Place de l’hemodiluition dans la prevention de la maladie thromboembolique. Phlebografie 41:825–829Google Scholar
  12. 12.
    Caroli GC et al (1994) Profilassi antitromboembolica e rischio emorragico in chirurgia ortopedica. Archivio di Ortopedia e Reumatologia 167(3): 125–130Google Scholar
  13. 13.
    Macouillard G et al (1989) Beneficies et risques des differentes methodes des prophylaxis avec ou sans heparinoides. Conferences de Consensus. Ann Fr Anesth Reanim 11:298–299Google Scholar
  14. 14.
    Cosmi B, Hirsh J (1994) Low molecular weight heparin. Curr Opin Cardiol 9(5):612–618PubMedCrossRefGoogle Scholar
  15. 15.
    Hirsh J (1990) From unfractionated heparins to low molecular weight heparins. Acta Chir Scand Suppl 556:42–50PubMedGoogle Scholar
  16. 16.
    Patrignani P, Volpi D, Ferrario R et al (1990) Effects of racemic, S-and R-indobufen on cyclooxygenase and lipooxygenase activities in human whole blood. Eur J Pharmacol 20; 191(l):83–88CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1996

Authors and Affiliations

  • B. Borghi
  • M. Montebugnoli
  • N. De Simone
  • G. Gargioni
  • M. A. Feoli

There are no affiliations available

Personalised recommendations